Recent medical interest in the role of Low Dose Naltrexone (a drug previously used to treat Alcohol and Opiate dependence) has filtered down to the management of chronic immune-modulated diseases such as Mast Cell Activation and Chronic Fatigue Syndrome. Naltrexone has been used for many years to treat addiction to Alcohol,  Morphine and Opiate analgesics, but researchers have found that at low dose, Naltrexone seems to have a beneficial effect in chronic pain and fatigue in Chronic Fatigue Syndrome and also used with benefit in some Auto-immune diseases.  So far, no convincing clinical studies have shown a beneficial role in Mast Cell Activation Syndrome (MCAS), where numerous symptoms may overlap with Chronic Fatigue Syndrome. However,  its an interesting ongoing medical research area to monitor, as Naltrexone is very cheap when compared with other suggested treatments, including monoclonal antibodies such as Omalizumab.

BMJ case reports – Reference: